2020
DOI: 10.1080/14740338.2020.1721456
|View full text |Cite
|
Sign up to set email alerts
|

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
80
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 115 publications
(85 citation statements)
references
References 75 publications
0
80
0
1
Order By: Relevance
“…Therefore, inhibition of AChE is suggested to be a promising strategy [3], which restores the memory deficits in AD patients. Despite repeated failures in the formulation of preventive and disease-modifying therapies, the AChE inhibitors appear to play a crucial role in controlling the symptoms and potentially slowing the rate of AD progression [4]. Notably, research also suggested that people with mild cognitive impairment (MCI) and dementia exhibited an increased risk of developing anxiety and depression as compared to people with normal cognitive function [5].…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, inhibition of AChE is suggested to be a promising strategy [3], which restores the memory deficits in AD patients. Despite repeated failures in the formulation of preventive and disease-modifying therapies, the AChE inhibitors appear to play a crucial role in controlling the symptoms and potentially slowing the rate of AD progression [4]. Notably, research also suggested that people with mild cognitive impairment (MCI) and dementia exhibited an increased risk of developing anxiety and depression as compared to people with normal cognitive function [5].…”
Section: Introductionmentioning
confidence: 99%
“…It has been reported that loss of cholinergic neurons contributes to memory and attention deficits, which could lead to disease progression and clinical condition aggravation [ 28 ]. Cholinesterase inhibitor therapy has been developed as the standard and predominant treatment for relieving symptoms and possibly slowing down disease progression of AD [ 29 , 30 ]. Thus, drugs that act on the neurotransmitter transporter may represent a promising option to relieve and cure patients with AD.…”
Section: Discussionmentioning
confidence: 99%
“…Memantine, a non-competitive NMDA antagonist, proved to improve learning and memory by restoring homeostasis in the glutamatergic system [ 84 ]. The rest of them besides memantine are cholinesterase inhibitors (ChEIs) and are first-line, symptomatic treatments of the disease, with gastrointestinal side effects as the most common adverse reactions [ 85 ]. Ischemic stroke is by far the most common type of stroke, which ranks fifth among all causes of mortality.…”
Section: Nervous System Diseasesmentioning
confidence: 99%